CN107343925B - Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof Download PDFInfo
- Publication number
- CN107343925B CN107343925B CN201710669255.0A CN201710669255A CN107343925B CN 107343925 B CN107343925 B CN 107343925B CN 201710669255 A CN201710669255 A CN 201710669255A CN 107343925 B CN107343925 B CN 107343925B
- Authority
- CN
- China
- Prior art keywords
- heart failure
- traditional chinese
- chinese medicine
- chronic heart
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating chronic heart failure, which is prepared from the following raw materials in parts by weight: 1-25g of red ginseng, 5-40g of astragalus root, 5-28g of cassia twig, 25-70g of euonymus fortunei, 5-40g of hispid fig, 5-28g of ligusticum wallichii, 5-40g of poria cocos, 5-28g of semen lepidii, 5-28g of radix polygonati officinalis and 3-20g of pseudo-ginseng. The invention also discloses a preparation method of the traditional Chinese medicine composition for treating chronic heart failure. The traditional Chinese medicine composition has the advantages of simple and easily-obtained raw materials, has the effects of tonifying qi and yin, clearing channels, warming yang and promoting diuresis, and has good curative effect, quick response and small toxic and side effects in the treatment process of chronic heart failure; has positive significance for developing the strong medicine characteristics and improving the clinical prevention and treatment level of CHF.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic heart failure and a preparation method thereof.
Background
Chronic Heart Failure (CHF) is a group of syndromes in which various organic or functional heart diseases impair ventricular filling or ejection ability, and is the terminal stage of development of various cardiovascular system diseases. According to statistics, about 450 million CHF patients exist in China at present, and the CHF patients are a very large patient population. With the wide popularization and application of the CHF western medicine prevention and treatment guidelines, the annual survival rate of CHF patients has been gradually improved, the rescue success rate in the acute exacerbation period of CHF has also been obviously improved, but the long-term effect is still not ideal. Even if the treatment is performed fully following the guidelines, the 5-year survival rate of heart failure is still less than 50%, which is similar to common malignant tumors such as breast cancer, colorectal cancer and the like, and is also called as a malignant disease in cardiovascular diseases. Although the treatment of CHF is of widespread interest, new CHF-related drugs have progressed very slowly, statistically since the nineties of the 20 th century the angiotensin receptor antagonists were emerging, and the only ivabradine that has proven effective to date and began to be used clinically. Therefore, in recent years, authoritative experts in the fields of Chinese medicine and western medicine in China all think that the combination of Chinese and western medicine will open a new situation of treating CHF in China, and the modernization research of Chinese medicines with curative effect is promoted for the first time to achieve the aim.
The traditional Chinese medicine considers that the basic pathogenesis of CHF is the deficiency of the origin and the excess of the origin, the deficiency of qi is the origin, and stasis, water and phlegm are the targets, and run through the generation and development of CHF. Therefore, the method for treating CHF by tonifying qi, warming yang, promoting blood circulation and inducing diuresis is widely applied clinically. A study published in International authoritative journal, journal of American society for cardiology, 2013 shows that the level reduction of NT-proBNP of patients in a Qili cardiotonic capsule treatment group is far superior to that of a control group which only uses western medicines, the cardiac function of CHF patients is obviously improved, and the potential of traditional Chinese medicines in prevention and treatment of CHF is displayed. The Chinese patent medicine has the characteristics of simplicity, convenience and low cost, is particularly suitable for CHF patients to use for a long time, but CHF has the characteristics of more basic diseases, more complications and the like as the final stage of occurrence and development of all cardiovascular diseases, has complicated and changeable clinical manifestations, has small quantity of Chinese patent medicines for preventing and treating CHF on the market at present, and is far from meeting the clinical requirements of preventing and treating CHF by combining Chinese and western medicines.
Zhuang medicine is planted in Guangxi, has strong regional characteristics, accumulates abundant knowledge and experience of disease prevention, diagnosis, medical treatment and drug application in long-term medical practice, and is widely accepted by society. However, the research on systematic preparations for preventing and treating CHF by Zhuang medicine is not available at present, and if effective patent drugs with Zhuang medicine characteristics for treating CHF can be developed, the research has positive significance for developing the Zhuang medicine characteristics and improving the clinical prevention and treatment level of CHF.
Disclosure of Invention
The invention aims to: aiming at the existing problems, the traditional Chinese medicine composition for treating chronic heart failure is provided, has precise and appropriate compatibility, has the effects of tonifying qi and yin, clearing channels, warming yang and promoting diuresis, and has good curative effect, quick response and small toxic and side effects in the treatment process.
In order to achieve the purpose of the invention, the technical scheme adopted by the invention is as follows:
a traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 1-25g of red ginseng, 5-40g of astragalus root, 5-28g of cassia twig, 25-70g of euonymus fortunei, 5-40g of hispid fig, 5-28g of ligusticum wallichii, 5-40g of poria cocos, 5-28g of semen lepidii, 5-28g of radix polygonati officinalis and 3-20g of pseudo-ginseng.
Preferably, the traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 5-15g of red ginseng, 14-26g of astragalus, 10-20g of cassia twig, 38-52g of euonymus fortunei, 14-26g of hispid fig, 10-20g of ligusticum wallichii, 14-26g of poria cocos, 10-20g of semen lepidii, 10-20g of radix polygonati officinalis and 5-16 parts of pseudo-ginseng.
Preferably, the traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 7g of red ginseng, 22g of astragalus, 15g of cassia twig, 40g of euonymus fortunei, 20g of hispid fig, 13g of ligusticum wallichii, 20g of poria cocos, 15g of pepperweed seed, 15g of polygonatum odoratum and 8g of panax notoginseng.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic heart failure, which comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 8-10 times of the total amount of the Chinese medicinal materials, soaking for 15-20min, decocting for 60min, and boiling under 0.05-0.06 Mpa; filtering to obtain medicinal liquid, adding 4-5 times of water into the water extraction tank, decocting for 50min under boiling pressure of 0.02-0.03MPa, and filtering to obtain medicinal liquid;
(3) mixing and concentrating the two liquid medicines into 500-600mL decoction.
Preferably, the invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic heart failure, which comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 8-10 times of the total amount of the Chinese medicinal materials, soaking for 15-20min, decocting for 60min, and boiling under 0.05-0.06 Mpa; filtering to obtain medicinal liquid, adding 4-5 times of water into the water extraction tank, decocting for 50min under boiling pressure of 0.02-0.03MPa, and filtering to obtain medicinal liquid;
(3) mixing the two medicinal liquids, placing in a concentration tank, concentrating to obtain soft extract, and concentrating at 70-80 deg.C;
(4) vacuum drying the soft extract, pulverizing into fine powder, adding starch, mixing, and making into capsule shell with 1000 granules.
Preferably, the filtration is rough filtration and then membrane filtration with the pore size of 10-50 μm.
Preferably, the relative density of the thick paste at the temperature of 60-80 ℃ is 1.15-1.25.
Preferably, the particle size of the fine powder is 100-150 μm.
Zhuang Yi theory holds that Longlu (also called as Xulu) governs the circulation of blood, and uses the heart head as the hub to connect the valley, water passage, air passage and fire passage of human body, and the three parts of heaven, human and earth, and its function is mainly to transport nutrition to the viscera, bones and muscles. "le" circulates in the dragon's road to nourish the organs, tissues, organs, sense organs and orifices. The dragon road has sufficient energy, the road is smooth, the regulation is proper, the qi of three parts of the human body can keep synchronous coordination and balance, and can keep synchronous with the natural qi of the sky and the earth, so that the qi and the blood are regulated smoothly, and the health state is kept.
The compatibility of the pharmaceutical composition of the invention is based on: the theory of Zhuang medicine considers that CHF belongs to the disease categories of 'A puzzles', 'heartbeats', and the like, and the diseases of 'A puzzles', 'heartbeats', and the like appear when the long-term illness, the old, the congenital deficiency, the emotional disorder or the invasion of toxic factors cause the energy of the long way to be reduced, the viscera function is regulated inaccurately or the way is blocked, and the qi and blood are unbalanced. If the function of dragon road is further reduced or even lost, the whole body is dried up in nutrient sources, and the energy of the corresponding viscera is tensed or even lost to cause the disease. The basic pathogenesis of the chronic hepatitis is exhaustion of the dragon road, invasion of various toxins, blockage of three roads and obstruction of three roads, and incapability of synchronizing the three qi of heaven and earth people. The dragon road exhaustion is mainly expressed by exhaustion of three roads and two roads and exhaustion of 'hist' (qi) 'le' and 'public' (yang) 'female'). The main manifestations of various toxic attacks are "le Du" and "shui Du", and the therapeutic principle is "Fu Du Gong" and "Tong Long Shu".
In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that:
according to the dialectical theory of Zhuang nationality, the invention has precise and appropriate compatibility, the euonymus fortunei can promote blood circulation to remove blood stasis and promote diuresis, and can promote the circulation of Qi and water channels, and the red ginseng can greatly supplement primordial qi and tonify 'hisi' (Qi) 'le' (blood) 'Gong' (Yang) 'mother' (Yin). Both herbs are considered yin and yang deficiency and excess, and they support the dragon to promote diuresis, so they are the monarch. Hispid of Ficus simplicissima lour and radix astragali can help monarch to support dragon and supplement holy, and hispid of cassia twig can help monarch to warm yang and supplement holy, and the three are all the mother medicines (ministerial medicines). The polygonatum can strengthen yin, strengthen the function of the male medicine for supporting and nourishing the dragon road, protect the female of the dragon road and prevent the male medicine from hurting the female; when Poria cocos is combined with red ginseng, the effect of supporting dragon to pass water is stronger; the rhizoma ligustici wallichii shovels toxic substances (blood) together, so that the dragon road is smoother; ting Li Zi has the effect of promoting qi and water passage. All the medicines have the effects of strengthening hispids and dredging the water. The traditional Chinese medicine composition has the advantages of simple and easily-obtained raw materials, has the effects of tonifying qi and yin, clearing channels, warming yang and promoting diuresis, and has good curative effect, quick response and small toxic and side effects in the treatment process of chronic heart failure; has positive significance for developing the strong medicine characteristics and improving the clinical prevention and treatment level of CHF.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail below with reference to preferred embodiments. It should be noted, however, that the numerous details set forth in the description are merely for the purpose of providing the reader with a thorough understanding of one or more aspects of the present invention, which may be practiced without these specific details.
Example 1
A traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 7g of red ginseng, 22g of astragalus, 15g of cassia twig, 40g of euonymus fortunei, 20g of hispid fig, 13g of ligusticum wallichii, 20g of poria cocos, 15g of pepperweed seed, 15g of polygonatum odoratum and 8g of panax notoginseng.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic heart failure, which comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 8 times of the total amount of the Chinese medicinal materials, soaking for 20min, decocting for 60min, and boiling under 0.05 Mpa; coarse-filtering with 100 mesh gauze, filtering with 50 μm membrane, collecting medicinal liquid, adding 5 times of water into water extraction tank, decocting for 50min under boiling pressure of 0.03MPa, coarse-filtering with 100 mesh gauze, filtering with 50 μm membrane, and collecting medicinal liquid;
(3) mixing the two liquid medicines, and concentrating to obtain 600mL decoction.
Example 2
A traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 7g of red ginseng, 22g of astragalus, 15g of cassia twig, 40g of euonymus fortunei, 20g of hispid fig, 13g of ligusticum wallichii, 20g of poria cocos, 15g of pepperweed seed, 15g of polygonatum odoratum and 8g of panax notoginseng.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic heart failure, which comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 8 times of the total amount of the Chinese medicinal materials, soaking for 20min, decocting for 60min, and boiling under 0.05 Mpa; coarse-filtering with 100 mesh gauze, filtering with 50 μm membrane, collecting medicinal liquid, adding 5 times of water into water extraction tank, decocting for 50min under boiling pressure of 0.03MPa, coarse-filtering with 100 mesh gauze, filtering with 50 μm membrane, and collecting medicinal liquid;
(3) mixing the two liquid medicines, placing the mixture into a concentration tank, concentrating the mixture to obtain thick paste with the relative density of 1.15 at the temperature of 60 ℃, and concentrating the thick paste at the temperature of 70 ℃;
(4) vacuum drying the soft extract, pulverizing into fine powder with particle size of 100 μm, adding starch into the fine powder, mixing, and making into capsule shell with size of 1000 granules.
Example 3
The other process methods of this embodiment are the same as those of embodiment 1, except that:
a traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 1g of red ginseng, 40g of astragalus, 5g of cassia twig, 25g of euonymus fortunei, 5g of hispid fig, 28g of ligusticum wallichii, 5g of poria cocos, 28g of pepperweed seed, 5g of polygonatum odoratum and 20g of pseudo-ginseng.
Example 4
The other process methods of this embodiment are the same as those of embodiment 1, except that:
a traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 25g of red ginseng, 5g of astragalus, 28g of cassia twig, 70g of euonymus fortunei, 40g of hispid fig, 5g of ligusticum wallichii, 40g of poria cocos, 5g of pepperweed seed, 28g of polygonatum odoratum and 3g of pseudo-ginseng.
Example 5
The other process methods of this embodiment are the same as those of embodiment 2, except that:
a traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 5g of red ginseng, 14g of astragalus, 20g of cassia twig, 38g of euonymus fortunei, 26g of hispid fig, 10g of ligusticum wallichii, 26g of poria cocos, 10g of pepperweed seed, 20g of polygonatum odoratum and 5g of pseudo-ginseng.
Example 6
The other process methods of this embodiment are the same as those of embodiment 2, except that:
a traditional Chinese medicine composition for treating chronic heart failure is prepared from the following raw materials in parts by weight: 15g of red ginseng, 26g of astragalus, 10g of cassia twig, 52g of euonymus fortunei, 14g of hispid fig, 20g of ligusticum wallichii, 14g of poria cocos, 20g of semen lepidii, 10g of radix polygonati officinalis and 16g of panax notoginseng.
Example 7
The other process methods of this embodiment are the same as those of embodiment 1, except that:
the invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic heart failure, which comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 10 times of the total amount of the Chinese medicinal materials, soaking for 15min, decocting for 60min, and boiling under 0.06Mpa steam pressure; coarse-filtering with 100 mesh gauze, filtering with 10 μm membrane, collecting medicinal liquid, adding 4 times of water into water extraction tank, decocting for 50min under boiling pressure of 0.02Mpa, coarse-filtering with 100 mesh gauze, filtering with 10 μm membrane, and collecting medicinal liquid;
(3) mixing the two liquid medicines, and concentrating to obtain 500mL decoction.
Example 8
The other process methods of this embodiment are the same as those of embodiment 1, except that:
the invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic heart failure, which comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 10 times of the total amount of the Chinese medicinal materials, soaking for 15min, decocting for 60min, and boiling under 0.06Mpa steam pressure; coarse-filtering with 100 mesh gauze, filtering with 10 μm membrane, collecting medicinal liquid, adding 4 times of water into water extraction tank, decocting for 50min under boiling pressure of 0.02Mpa, coarse-filtering with 100 mesh gauze, filtering with 10 μm membrane, and collecting medicinal liquid;
(3) mixing the two liquid medicines, placing the mixture into a concentration tank, and concentrating the mixture to obtain thick paste with the relative density of 1.25 at the temperature of 80 ℃, wherein the concentration temperature is 80 ℃;
(4) vacuum drying the soft extract, pulverizing into fine powder with particle size of 150 μm, adding starch into the fine powder, mixing, and making into capsule shell with size of 1000 granules.
The use method of the traditional Chinese medicine composition for treating chronic heart failure comprises the following steps: generally, the decoction is taken once a day, and each dose is 500mL and 600mL for morning and evening; the capsule is 2 granules each time, twice a day; 4 weeks is a course of treatment. Fishy, cold and spicy food is avoided during administration.
Toxicity testing of the Chinese medicinal composition of the present invention
(1) Acute toxicity test:
the Chinese medicinal decoction is administrated by intragastric administration to mice at 150g/kg, and no death and abnormal activity occur. Corresponding to 3 times/day and 6 tablets/time of clinical dosage, and each person calculates 800 times according to 50 kg. The traditional Chinese medicine composition decoction is administrated by intragastric administration to rats according to 80g/kg, no death occurs, no abnormal activity is seen, and the dosage is equivalent to more than 400 times of the clinical dosage.
(2) Long-term toxicity test:
the Chinese medicinal decoction is continuously administered to rats by gavage for 3 months at 40, 20 and 10 g/Kg/day, and has no obvious influence on hematology indexes; has no obvious influence on blood biochemical indexes; no obvious pathological changes are found in organ coefficients and pathological histological examination.
Observation of clinical efficacy
The clinical diagnosis of patients with chronic heart failure shows that the patients have 300 cases, the age of the patients is 150 cases above 50 years old (including) and 150 cases below 50 years old. Patients were randomly divided into three groups, wherein 1 group for treatment was administered with the decoction of the present invention in example 1 according to the course of treatment, 2 groups for treatment were administered with the capsule of the present invention in example 2 according to the course of treatment, and 3 groups for treatment were administered with the commercially available Qili cardiotonic capsule according to the instructions. The curative effect of the treatment 1 group, the treatment 2 group and the control group after treatment is compared and shown in the table 1. The standard of curative effect refers to the guiding principle of new drug research of traditional Chinese medicine. The effect is shown: the cardiac function is improved by more than 2 levels, but the standard of level I is not reached; the method has the following advantages: cardiac function is improved by level 1, but not to level I; and (4) invalidation: cardiac function was improved by less than 1 grade and chronic heart failure symptoms were not controlled.
TABLE 1
| Group of | Total number of people/example | Significant effects/examples | Effective/example | Invalid/example | Total effective rate/%) |
| Treatment 1 group | 100 | 83 | 15 | 2 | 98 |
| Treatment of 2 groups | 100 | 79 | 18 | 3 | 97 |
| Control group | 100 | 69 | 24 | 7 | 93 |
As can be seen from table 1, the treatment 1 and 2 groups had good efficacy, and the total effective rate was superior to that of the control group.
In conclusion, the traditional Chinese medicine composition has the advantages of simple and easily-obtained raw materials, has the effects of tonifying qi and yin, clearing channels, warming yang and promoting diuresis, and has good curative effect, quick response and small toxic and side effects in the treatment process of chronic heart failure; has positive significance for developing the strong medicine characteristics and improving the clinical prevention and treatment level of CHF.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be construed as the protection scope of the present invention.
Claims (7)
1. A traditional Chinese medicine composition for treating chronic heart failure is characterized in that: the feed is prepared from the following raw materials in parts by weight: 1-25g of red ginseng, 5-40g of astragalus root, 5-28g of cassia twig, 25-70g of euonymus fortunei, 5-40g of hispid fig, 5-28g of ligusticum wallichii, 5-40g of poria cocos, 5-28g of semen lepidii, 5-28g of radix polygonati officinalis and 3-20g of pseudo-ginseng;
the preparation method of the traditional Chinese medicine composition for treating chronic heart failure comprises the following steps:
(1) weighing the raw materials according to the proportion, and respectively crushing the raw materials into coarse particles for later use;
(2) placing coarse granular Chinese medicinal materials in water extraction tank, adding water 8-10 times of the total amount of the Chinese medicinal materials, soaking for 15-20min, decocting for 60min, and boiling under 0.05-0.06 Mpa; filtering to obtain medicinal liquid, adding 4-5 times of water into the water extraction tank, decocting for 50min under boiling pressure of 0.02-0.03MPa, and filtering to obtain medicinal liquid;
(3) mixing the two liquid medicines, concentrating, and making into 500-600mL decoction or capsule.
2. The traditional Chinese medicine composition for treating chronic heart failure according to claim 1, wherein the composition comprises: the feed is prepared from the following raw materials in parts by weight: 5-15g of red ginseng, 14-26g of astragalus, 10-20g of cassia twig, 38-52g of euonymus fortunei, 14-26g of hispid fig, 10-20g of ligusticum wallichii, 14-26g of poria cocos, 10-20g of semen lepidii, 10-20g of radix polygonati officinalis and 5-16 parts of pseudo-ginseng.
3. The traditional Chinese medicine composition for treating chronic heart failure according to claim 1, wherein the composition comprises: the feed is prepared from the following raw materials in parts by weight: 7g of red ginseng, 22g of astragalus, 15g of cassia twig, 40g of euonymus fortunei, 20g of hispid fig, 13g of ligusticum wallichii, 20g of poria cocos, 15g of pepperweed seed, 15g of polygonatum odoratum and 8g of panax notoginseng.
4. The traditional Chinese medicine composition for treating chronic heart failure according to any one of claims 1 to 3, wherein: the preparation process of the capsule further comprises:
(1) mixing the two medicinal liquids, placing in a concentration tank, concentrating to obtain soft extract, and concentrating at 70-80 deg.C;
(2) vacuum drying the soft extract, pulverizing into fine powder, adding starch, mixing, and making into capsule shell to obtain 1000 granules.
5. The traditional Chinese medicine composition for treating chronic heart failure according to claim 1, wherein the composition comprises: the filtration is coarse filtration and then membrane filtration with the aperture of 10-50 μm.
6. The traditional Chinese medicine composition for treating chronic heart failure according to claim 4, wherein the composition comprises the following components: the relative density of the thick paste at the temperature of 60-80 ℃ is 1.15-1.25.
7. The traditional Chinese medicine composition for treating chronic heart failure according to claim 4, wherein the composition comprises the following components: the particle size of the fine powder is 100-150 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710669255.0A CN107343925B (en) | 2017-08-08 | 2017-08-08 | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710669255.0A CN107343925B (en) | 2017-08-08 | 2017-08-08 | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107343925A CN107343925A (en) | 2017-11-14 |
| CN107343925B true CN107343925B (en) | 2020-10-13 |
Family
ID=60257468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710669255.0A Active CN107343925B (en) | 2017-08-08 | 2017-08-08 | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107343925B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109646573A (en) * | 2019-01-23 | 2019-04-19 | 广西中医药大学 | A kind of enrich blood supports the strong drug composition and preparation method thereof of essence |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102416101A (en) * | 2011-12-09 | 2012-04-18 | 天津市石天药业有限责任公司 | Chinese medicinal composition for treating heart failure and preparation method as well as application thereof |
-
2017
- 2017-08-08 CN CN201710669255.0A patent/CN107343925B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102416101A (en) * | 2011-12-09 | 2012-04-18 | 天津市石天药业有限责任公司 | Chinese medicinal composition for treating heart failure and preparation method as well as application thereof |
Non-Patent Citations (4)
| Title |
|---|
| 加减木防己汤对慢性充血性心力衰竭阳虚血瘀水停证患者BNP及EF值的影响;钱晶等;《北京中医药》;20110831;第30卷(第8期);第567-569页，尤其是第567页右栏最后一段、第568页左栏第1段、第569页左栏第2段 * |
| 加用扶芳藤益心汤对慢性心衰患者的生存质量、左室射血分数及脑钠尿肽的影响;雷贻禄等;《广西中医药》;20161031;第39卷(第5期);第12-14页 * |
| 复方扶芳藤合剂药理研究与临床应用;刘源焕等;《中国民族民间医药》;20141231(第6期);第26-28页，尤其是第26页左栏第1段、右栏第4段 * |
| 红参茶治疗缓慢型心衰10例的观察;周晓军;《光明中医》;20011231;第16卷(第2期);第52页，尤其是左栏第3段、右栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107343925A (en) | 2017-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN103749822A (en) | Fructus ligustri lucidi health-care tea for lowering blood pressure and lipid and preparation method thereof | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN107343925B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN105796845A (en) | Application of medicine composition in preparing medicine for treating female climacteric syndromes | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN104758578A (en) | Traditional Chinese medicine composition for treating palpitation | |
| CN100574799C (en) | Radix Ginseng cold limbs injection and preparation method | |
| CN104055963A (en) | Fat loss traditional Chinese medicine composition and preparation method thereof | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN102319401A (en) | A kind of Chinese medicine composition that is used for benefiting QI for activating blood circulation, spleen invigorating collateral dredging and preparation method thereof | |
| CN106474297A (en) | Improve pharmaceutical composition of gerontal patient's postoperative cognition disorders and preparation method thereof | |
| CN105687567A (en) | Preparation for preventing and treating diarrhea caused by chemotherapy and preparation method of preparation | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN104208570A (en) | Traditional Chinese medicinal composition for treating heart failure, and preparation method thereof | |
| CN104547695B (en) | It is a kind of for treating the pharmaceutical composition and its application of trigeminal neuralgia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |